Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

被引：5
|
作者：
Buecklein, Veit
Blumenberg, Viktoria
Ackermann, Josephine
Schmidt, Christian
Rejeski, Kai
Mueller, Niklas
Reischer, Anna
von Baumgarten, Louisa
Schoeberl, Florian
Humpe, Andreas
von Bergwelt, Michael
Subklewe, Marion
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Single- center experience with both Axicabtagene-ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL): Number of prior therapy lines is not associated with progression-free survival
    Buecklein, V
    Blumenberg, V
    Ackermann, J.
    Schmidt, C.
    Rejeski, K.
    Ruzicka, M.
    Mueller, N.
    Reischer, A.
    Busch, G.
    von Baumgarten, L.
    Humpe, A.
    von Bergwelt, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 61 - 62
  • [2] INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)
    Oluwole, O.
    Jansen, J. P.
    Lin, V
    Chan, K.
    Navale, L.
    Kim, J. J.
    Locke, F. L.
    VALUE IN HEALTH, 2019, 22 : S522 - S522
  • [3] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
    Ball, G.
    Kuruvilla, J.
    Boodoo, C.
    Jain, M. D.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [4] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
  • [5] Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
    Logue, Jennifer Marilyn
    Krivenko, Gabriel S.
    Larson, Victoria
    Bachmeier, Christina A.
    Chavez, Julio C.
    Davila, Marco L.
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien D.
    Pinilla-Ibarz, Javier
    Shah, Bijal D.
    Dholaria, Bhagirathbhai R.
    Jain, Michael D.
    Locke, Frederick Lundry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL, Real World Data, Single Institution Experience
    Alasbali, Reem
    Nasiri, Abdulrahman
    Adam, Alfadil
    Alhayli, Saud
    Chaudhri, Naeem A.
    Alshaibani, Alfadel
    Albabtain, Abdulwahab
    Samarkandi, Hadeel
    Saad, Ayman
    Alamer, Abdullah
    Elhassan, Tusneem Ahmed M.
    Alzahrani, Hazza A.
    Ahmed, Syed Osman
    Rasheed, Walid
    Elfakih, Riad
    Aljurf, Mahmoud
    Ali, D. Alahmari
    BLOOD, 2023, 142
  • [7] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
    Topp, Max
    Van Meerten, Tom
    Houot, Roch
    Minnema, Monique C.
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin
    Avivi, Irit
    Kuruvilla, John
    Duhrsen, Ulrich
    Chu, Rachel
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose'
    BLOOD, 2019, 134
  • [8] Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.
    Yang, Hongbo
    Qi, Cynthia Zhengyun
    Dalal, Anand
    Bollu, Vamsi
    Zhang, Jie
    Zhang, Su
    Lim, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Preliminary results of earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma
    Topp, M. S.
    van Meerten, T.
    Wermke, M.
    Lugtenburg, P. J.
    Minnema, M. C.
    Song, K. W.
    Thieblemont, C.
    Jiang, Y.
    Plaks, V
    Kerber, A.
    Kersten, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 65 - 66
  • [10] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345